Background/Aims: Pregnancy-associated plasma protein-A (PAPP-A) is a putative marker of atheroma instability and ischaemic myocardial stress prior to necrosis. Total PAPP-A (tPAPP-A) levels in acute coronary syndromes predict adverse outcomes. However, free PAPP-A (fPAPP-A) predominates in the circulation. Ischaemic haemodialysis (HD)-induced cardiac injury (myocardial stunning) is common and is associated with markers of myocardial necrosis, inflammation, cardiovascular events and mortality. Coronary plaque instability in pathophysiology of HD-induced myocardial stunning has not been studied. We aimed to investigate the relationship of fPAPP-A with stunning and mortality. Methods: 130 prevalent patients from two HD centres (Finland and UK) were studied. Pre-HD free, complexed and total PAPP-A were measured by immunoassay. A subset of 62 patients underwent echocardiography to assess HD-induced myocardial stunning. The mean duration of follow-up was 407 ± 98 days. Results: fPAPP-A was elevated (median: 3.45 mIU/l) and correlated with dialysis vintage (r = 0.391, p < 0.001), cardiac troponin T (cTnT; r = 0.29, p = 0.001) and cardiac troponin I (cTnI; r = 0.22, p = 0.01). PAPP-A was not related to stunning. Dialysis vintage and cTnT independently predicted Ln fPAPP-A (model R = 0.463). fPAPP-A, cTnT and age independently predicted death (Nagelkerke R2 = 0.362). Conclusions: fPAPP-A, a novel predictor of HD-related mortality, demonstrates better prognostic power than tPAPP-A. Coronary plaque instability may contribute to sub-lethal myocardial injury, but may not be critical in pathogenesis of HD-induced ischaemic cardiac injury.

Keywords:
Acute coronary syndromes, Myocardial stunning, Pregnancy-associated plasma protein-A
1.
Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. J Nephrol 1998;11:239-245.
2.
Sigrist MK, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007;2:1241-1248.
3.
McIntyre CW, Burton JO, Selby NM, Leccisotti L, Korsheed S, Baker CS, Camici PG: Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 2008;3:19-26.
4.
Burton JO, Jefferies HJ, Selby NM, McIntyre CW: Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009;4:914-920.
5.
Burton JO, Jefferies HJ, Selby NM, McIntyre CW: Haemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009;4:1925-1931.
6.
Hothi DK, Rees L, Marek J, Burton J, McIntyre CW: Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. Clin J Am Soc Nephrol 2009;4:790-797.
7.
Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS: Pregnancy-associated plasma protein a as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-1029.
8.
Lund J, Qin QP, Ilva T, Pettersson K, Voipio-Pulkki LM, Porela P, Pulkki K: Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003;108:1924-1926.
9.
Coskun A, Bicik Z, Duran S, Alcelik A, Soypacaci Z, Yavuz O, Oksuz S: Pregnancy-associated plasma protein A in dialysis patients. Clin Chem Lab Med 2007;45:63-66.
10.
Kalousova M, Horejsi M, Fialova L, Soukupova J, Sulkova S, Malbohan I, Tesar V, Zima T: Increased levels of pregnancy-associated plasma protein A are associated with mortality in hemodialysis patients: preliminary results. Blood Purif 2004;22:298-300.
11.
Etter C, Straub Y, Hersberger M, Raz HR, Kistler T, Kiss D, Wuthrich RP, Gloor HJ, Aerne D, Wahl P, Klaghofer R, Ambuhl PM: Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis. Eur Heart J 2010;31:354-359.
12.
Qin QP, Kokkala S, Lund J, Tamm N, Voipio-Pulkki LM, Pettersson K: Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy. Clin Chem 2005;51:75-83.
13.
Wittfooth S, Qin QP, Lund J, Tierala I, Pulkki K, Takalo H, Pettersson K: Immunofluorometric point-of-care assays for the detection of acute coronary syndrome-related noncomplexed pregnancy-associated plasma protein A. Clin Chem 2006;52:1794-1801.
14.
Tertti R, Wittfooth S, Porela P, Airaksinen KE, Metsarinne K, Pettersson K: Intravenous administration of low molecular weight and unfractionated heparin elicits a rapid increase in serum pregnancy-associated plasma protein A. Clin Chem 2009;55:1214-1217.
15.
Bosch JG, Savalle LH, van Burken G, Reiber JH: Evaluation of a semiautomatic contour detection approach in sequences of short-axis two-dimensional echocardiographic images. J Am Soc Echocardiogr 1995;8:810-821.
16.
Dasselaar JJ, Slart RH, Knip M, Pruim J, Tio RA, McIntyre CW, de Jong PE, Franssen CF: Haemodialysis is associated with a pronounced fall in myocardial perfusion. Nephrol Dial Transplant 2009;24:604-610.
17.
Coskun A, Duran S, Apaydin S, Bulut I, Sariyar M: Pregnancy-associated plasma protein-A: evaluation of a new biomarker in renal transplant patients. Transplant Proc 2007;39:3072-3076.
18.
Sangiorgi G, Mauriello A, Bonanno E, Oxvig C, Conover CA, Christiansen M, Trimarchi S, Rampoldi V, Holmes DR Jr, Schwartz RS, Spagnoli LG: Pregnancy-associated plasma protein-A is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. J Am Coll Cardiol 2006;47:2201-2211.
19.
Danzig V, Mikova B, Kuchynka P, Benakova H, Zima T, Kittnar O, Skrha J, Linhart A, Kalousova M: Levels of circulating biomarkers at rest and after exercise in coronary artery disease patients. Physiol Res 2010;59:385-392.
20.
Kalousova M, Bartosova K, Zima T, Skibova J, Teplan V, Viklicky O: Pregnancy-associated plasma protein A and soluble receptor for advanced glycation end products after kidney transplantation. Kidney Blood Press Res 2007;30:31-37.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.